Celsion Corporation
 (CLSN)

- NASDAQ
What's your position on ?
Bullish
Bearish
Why are you ish?
Skip
Post
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Dec. 16, 2015, 9:14 AM
    | Dec. 16, 2015, 9:14 AM
  • Nov. 12, 2015, 6:51 AM
    • Celsion (NASDAQ:CLSN) shares will begin trading on the TASE today. Based on its market cap, it will be included in two TASE equity indexes: the TA-BlueTech and TA-Biomed.
    • Chairman, President & CEO Michael Tardugno says, "We believe that the dual listing on the TASE will help us to open a new access point for our shares in the Israeli market that is becoming a center for biomed and emerging technology companies. The new listing also offers an opportunity to expand and diversify our shareholder base by increasing our exposure and improving or accessibility to Israeli investors."
    | Nov. 12, 2015, 6:51 AM | 1 Comment
  • Nov. 5, 2015, 10:40 AM
    • Celsion Corp. (CLSN -1%) Q3 results: Revenues: $0.1M (unch); R&D Expense: $2.9M (-37.0%); SG&A: $1.5M (-25.0%); Operating Loss: ($4.2M) (+37.3%); Net Loss: ($4.3M) (+37.7%); Loss Per Share: ($0.19) (+52.5%); Quick Assets: $7.6M (-40.2%).
    • No guidance given.
    | Nov. 5, 2015, 10:40 AM
  • Nov. 5, 2015, 8:06 AM
    • Celsion (NASDAQ:CLSN): Q3 EPS of -$0.19 may not be comparable to consensus of -$0.26.
    • Revenue of $0.13M (flat Y/Y) beats by $0.02M.
    | Nov. 5, 2015, 8:06 AM
  • Oct. 12, 2015, 10:44 AM
    • Thinly traded nano cap Celsion (CLSN +9.2%) moves up on a healthy 10x surge in volume in response to its announcement of positive preclinical results for its GEN-1 IL-12 immunotherapy. Specifically, the combination of GEN-1 IL-12 with Roche's (OTCQX:RHHBY +0.7%) Avastin (bevacizumab) and J&J's (JNJ +0.9%) Doxil (doxorubicin HCl liposome injection) showed a greater than 98% reduction in tumor burden compared to the combination of Avastin and Doxil alone in an ovarian cancer cell line called SKOV3 implanted into immunocompromised mice.
    • GEN-1 is an immunotherapy consisting of an interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery system. It is administered via an intraperitoneal (body cavity) injection.
    • The company is currently enrolling patients in a Phase 1b trial called OVATION. A Phase 1/2 combination study should commence in mid-2016.
    | Oct. 12, 2015, 10:44 AM | 1 Comment
  • Oct. 12, 2015, 9:13 AM
    | Oct. 12, 2015, 9:13 AM | 6 Comments
  • Aug. 10, 2015, 9:36 AM
    • Celsion Corp. (CLSN) Q2 results: Revenues: $0.1M (unch); R&D Expense: $3.6M (+12.5%); SG&A: $1.8M (-21.7%); Operating Loss: ($5.2M) (+18.8%); Net Loss: ($5.7M) (+14.9%); Loss Per Share: ($0.27) (+28.9%); Quick Assets: $12M (-5.5%).
    • No guidance given.
    | Aug. 10, 2015, 9:36 AM
  • Aug. 10, 2015, 8:02 AM
    • Celsion (NASDAQ:CLSN): Q2 EPS of -$0.27 beats by $0.04.
    • Revenue of $0.13M (flat Y/Y) beats by $0.02M.
    | Aug. 10, 2015, 8:02 AM | 1 Comment
  • Aug. 6, 2015, 9:27 AM
    • Thinly traded nano cap Celsion (NASDAQ:CLSN) is up 8% premarket on light volume in response to its announcement of the latest overall survival (OS) data from its Phase 3 study, called HEAT, evaluating ThermoDox in combination with radiofrequency ablation (RFA) in primary liver cancer.
    • As of July 15, treatment with the combination showed a 58% improvement in overall survival in a subgroup of subjects (n=285/701) compared to RFA alone (p=0.0198). Median OS for the ThermoDox cohort was 79 months versus 53.6 months in the RFA-only cohort.
    • A post-hoc slice-and-dice of the data showed a ThermoDox treatment effect in Chinese patients with single lesions but it was not statistically significant.
    | Aug. 6, 2015, 9:27 AM
  • Aug. 6, 2015, 9:15 AM
    | Aug. 6, 2015, 9:15 AM | 9 Comments
  • Jul. 15, 2015, 10:36 AM
    • Celgene's (CELG +9.5%) $7.2B deal for Receptos (RCPT +10.3%) is “a great acquisition at a great price," Nomura analysts say, as ozanimod could enable CELG's inflammation and immunology franchise to double peak sales to $10B and reduce reliance on Revlimid to drive future growth, and the acquisition price of less than 2x peak sales is a steep discount relative to recent comparisons.
    • Wedbush analyst Liana Moussatos sees plenty of potential upside to justify a rival bidder stepping in for RCPT, noting that she had estimated the company could be valued at $348/share, or ~$10.9B, in a buyout, substantially more than CELG's $232 offer.
    • The deal is boosting some biotech names (IBB +1.9%), including PTC Therapeutics (PTCT +11.7%), Celsion (CLSN +7.1%) and Arena Pharmaceuticals (ARNA +6.7%).
    | Jul. 15, 2015, 10:36 AM | 23 Comments
  • Jul. 15, 2015, 9:15 AM
    | Jul. 15, 2015, 9:15 AM | 4 Comments
  • Jul. 14, 2015, 9:19 AM
    | Jul. 14, 2015, 9:19 AM
  • Jul. 6, 2015, 9:10 AM
    | Jul. 6, 2015, 9:10 AM | 1 Comment
  • May 28, 2015, 10:49 AM
    • Celsion (CLSN -3.8%) secures commitments from two institutional investors to directly purchase an aggregate of $8M in common stock at market prices, specifically 3M shares at $2.675 per share. Concurrently, the investors will receive 3M warrants to purchase 0.65 shares of common stock (1.95M total shares) at $2.60 per share.
    • Closing date is June 1. Net proceeds of ~$7.3M will be used for general corporate purposes.
    | May 28, 2015, 10:49 AM
  • May 12, 2015, 8:47 AM
    • Celsion Corp. (CLSN +2%) Q1 results: Revenues: $0.1M (unch); R&D Expense: $4.5M (+55.2%); SG&A: $2M (-16.7%); Operating Loss: ($6.4M) (-23.1%); Net Loss: ($7M) (-29.6%); Loss Per Share: ($0.35) (-6.1%); Quick Assets: $7.6M (-40.2%).
    • No guidance given.
    | May 12, 2015, 8:47 AM
Company Description
Celsion Corp is a fully-integrated oncology drug development company. The Company is engaged in developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and RNA- or DNA-based therapies.
Sector: Healthcare
Industry: Biotechnology
Country: United States